Lipoprotein(a): more interesting than ever after 50 years
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease; we highlight the most recent research initiatives that have sought to define Lp(a)-dependent pathogenicity as well as pharmacologic approaches to lowering Lp(a). RECENT FINDINGS: Recent large-scale meta-analyses have confirmed elevated Lp(a) concentrations to be a moderate but consistent prospective coronary heart disease (CHD) risk factor. The Mendelian randomization approach has also associated LPA variants with Lp(a) concentration and CHD risk. Discoveries linking Lp(a) to oxidized phospholipid burden have implicated a proinflammatory role for Lp(a) hinting at a new mechanism underlying the association with CHD risk, which adds to previous atherogenic and thrombogenic mechanisms. Most existing Lp(a)-lowering drug treatments almost always show simultaneous effects on other lipoproteins, making it difficult to assign any clinical outcome specifically to the effects of Lp(a) lowering. Early experiments with antisense oligonucleotides targeting apolipoprotein(a) mRNA seem to indicate the pleiotropic effects of Lp(a) reduction on LDL and HDL in mice. The mechanism linking Lp(a) concentration with concentrations of other blood lipids remains unknown but may provide an insight into Lp(a) metabolism. SUMMARY: Despite the wealth of epidemiologic evidence supporting Lp(a) concentration as a CHD risk factor, the lack of a definitive functional mechanism involving an Lp(a)-dependent pathway in CHD pathogenesis has limited the potential clinical connotation of Lp(a). However, the application of novel technologies to the long-standing mysteries of Lp(a) biology seems to provide the opportunity for expanding our understanding of Lp(a) and its complex role in cardiovascular health.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a LDL-like particle in which the apoB protein is linked by a disulfide bridge to apo(a)47.”
From Calcific aortic stenosis (2016) · cites this paper as [47]
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [222]
In the citing paper
“When the size of apolipoprotein (a) [apo(a)] is small, the concentration of Lp(a) is high, and there is a high risk of CVD.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [222]
In the citing paper
“Lp(a) is an independent risk factor for CAD and stroke.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [222]
In the citing paper
“High Lp(a) concentrations are found in patients with FH, and it is presumed that hyper-Lp (a)-lipoproteinemia further increases the risk for CVD in patients with FH222).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [222]
Citations
Cites
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886 · cited 1×
“The range of genomic variation at LPA includes copy number variation (CNV), specifically a highly polymorphic region that results from variable numbers of tandemly repeated exon sequences that encode kringle IV type 2 (KIV-2) of apo(a) [8], a pentanucleotide repeat in the LPA promoter that affects gene expression [9],…”
BackgroundRidker, P. M., Buring, J. E., Rifai, N., & Cook, N. R. (2007) · JAMA · doi:10.1001/jama.297.6.611 · Cited by 1,814
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671 · cited 2×
“[12] described particularly strong and independent associations between CHD and two LPA variants, namely rs10455872, which is a noncoding intronic SNP, and rs3798220, which is a missense variant encoding an amino acid substitution (Ile4399Met) in the apo(a) protease-like domain.”
BackgroundBoerwinkle, E., Leffert, C. C., Lin, J., Lackner, C., Chiesa, G., & Hobbs, H. H. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115855 · Cited by 962
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M., & Cook, N. R. (2008) · Circulation · doi:10.1161/circulationaha.108.814251 · Cited by 841
Genest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., Couture, P., Dufour, R., Fodor, G., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 768
Self-citation
Research works printed but not linked: 1
- Gudnason, 2009, Lipoprotein(a): a causal independent risk factor for coronary heart disease Curr Opin C, ardiol, 24, 490
Cited by
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD
Datta, S., Cano, M., Ebrahimi, K., Wang, L., & Handa, J. T. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.002 · Cited by 802
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Kettunen, J., Demirkan, A., Würtz, P., Draisma, H. H. M., Haller, T., Rawal, R., Vaarhorst, A., Kangas, A. J., Lyytikäinen, L.-P., Pirinen, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11122 · Cited by 738
van der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., Van den Bossche, J., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 674
Self-citationSeidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
Nordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
The complex molecular genetics of familial hypercholesterolaemia
Berberich, A. J., & Hegele, R. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0052-6 · Cited by 290
Self-citationLipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?
Boffa, M. B., & Koschinsky, M. L. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r060582 · Cited by 309
“As differences in the genetic architecture of LPA between different ethnic groups (such as prevalence of differently-sized isoforms) are incompletely understood (139), it”
BackgroundSelf-citationDeterminants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)
Leibundgut, G., Scipione, C., Yin, H., Schneider, M., Boffa, M. B., Green, S., Yang, X., Dennis, E., Witztum, J. L., Koschinsky, M. L., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m040733 · Cited by 243
Self-citationLipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease
Tsimikas, S., & Hall, J. L. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.038 · Cited by 234
Dyslipidemia in women with polycystic ovary syndrome
Kim, J. J., & Choi, Y. M. (2013) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2013.56.3.137 · Cited by 190
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Self-citationAntisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 132
Scipione, C. A., Sayegh, S. E., Romagnuolo, R., Tsimikas, S., Marcovina, S. M., Boffa, M. B., & Koschinsky, M. L. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060210 · Cited by 126
Self-citationVinci, P., Girolamo, F. G. D., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., Biasinutto, C., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186721 · Cited by 139
Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related macular degeneration.
Handa, J. T., Cano, M., Wang, L., Datta, S., & Liu, T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.07.013 · Cited by 112
MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma
Wiesner, P., Tafelmeier, M., Chittka, D., Choi, S.-H., Zhang, L., Byun, Y. S., Almazan, F., Yang, X., Iqbal, N., Chowdhury, P., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m036343 · Cited by 106
The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal?
Ye, Z., Haycock, P. C., Gurdasani, D., Pomilla, C., Boekholdt, S. M., Tsimikas, S., Khaw, K.-T., Wareham, N. J., Sandhu, M. S., & Forouhi, N. G. (2014) · Diabetes · doi:10.2337/db13-1144 · Cited by 105
Oxidation-Specific Biomarkers and Risk of Peripheral Artery Disease
Bertoia, M. L., Pai, J. K., Lee, J. H., Taleb, A., Joosten, M. M., Mittleman, M. A., Yang, X., Witztum, J. L., Rimm, E. B., Tsimikas, S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.047 · Cited by 98
Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study
Arora, P. K., Kalra, R., CALLAS, P. W., Alexander, K., Zakai, N. A., Wadley, V. G., Arora, G., D, B. M. K. M., Judd, S. E., & Cushman, M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311857 · Cited by 98
Lipoprotein(a) in Cardiovascular Diseases
Malaguarnera, M., Vacante, M., Russo, C., Malaguarnera, G., Antic, T., Malaguarnera, L., Bella, R., Pennisi, G., Galvano, F., & Frigiola, A. (2013) · BioMed Research International · doi:10.1155/2013/650989 · Cited by 87
Romagnuolo, R., Marcovina, S. M., Boffa, M. B., & Koschinsky, M. L. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m036566 · Cited by 86
Self-citationMetabolism: The road to inflammation and atherosclerosis
Ali, L., Schnitzler, J. G., & Kroon, J. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000550 · Cited by 86
When should we measure lipoprotein (a)?
Kostner, K. M., Marz, W., & Kostner, G. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht053 · Cited by 77
Genetics of Lipid and Lipoprotein Disorders and Traits
Dron, J. S., & Hegele, R. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0097-y · Cited by 77
Self-citationIn vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a)
Frischmann, M. E., Ikewaki, K., Trenkwalder, E., Lamina, C., Dieplinger, B., Soufi, M., Schweer, H., Schaefer, J. R., König, P., Kronenberg, F., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.031 · Cited by 75
Bajaj, A., Damrauer, S. M., Anderson, A. H., Xie, D., Budoff, M. J., Go, A. S., He, J., Lash, J. P., OJO, A. O., Post, W. S., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309920 · Cited by 69
Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics
Lee, R. G., Crosby, J., Baker, B. F., Graham, M. J., & Crooke, R. M. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9495-7 · Cited by 65
Emerging therapeutic agents to lower lipoprotein (a) levels
Kolski, B., & Tsimikas, S. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283598d81 · Cited by 63
Cholesterol-Lowering Agents: PCSK9 Inhibitors Today and Tomorrow
Rosenson, R. S., Hegele, R. A., & Koenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 61
Self-citationKyriakou, T., Seedorf, U., Goel, A., Hopewell, J. C., Clarke, R., Watkins, H., & Farrall, M. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303462 · Cited by 58
Sosnowska, B., Stępińska, J., Mitkowski, P. P., Bielecka-Dabrowa, A. M., Bobrowska, B., Budzianowski, J., Burchardt, P., Chlebus, K., Dobrowolski, P., Gąsior, M., et al. (2024) · Archives of Medical Science · doi:10.5114/aoms/183522 · Cited by 65
The current status of lipoprotein (a) in pregnancy: A literature review
Fanshawe, A., & Ibrahim, M. E. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.09.009 · Cited by 63
Alexandros, D. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160009 · Cited by 61
Xia, Q., Chen, Y., Yu, Z., Huang, Z., Yang, Y., Mao, A., & Qiu, W. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1186330 · Cited by 58
Kotani, K., Sahebkar, A., Serban, C., Andrica, F., Toth, P. P., Jones, S. R., Kostner, K., Blaha, M. J., Martin, S. S., Rysz, J., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.056 · Cited by 54
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 59
Dietary natural products as emerging lipoprotein(a)‐lowering agents
Momtazi‐Borojeni, A. A., Katsiki, N., Pirro, M., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28134 · Cited by 49
Lipoprotein (a), an independent cardiovascular risk marker
Saeedi, R., & Frohlich, J. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0024-x · Cited by 43
Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0360-6 · Cited by 42
Self-citationCho, T., Romagnuolo, R., Scipione, C. A., Boffa, M. B., & Koschinsky, M. L. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-08-0637 · Cited by 39
Self-citationAssociation between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults
Nam, J. S., Jo, S., Kang, S., Ahn, C. W., Kim, K. R., & Park, J. S. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.07.003 · Cited by 38
Lipoprotein(a) and cardiovascular disease in diabetic patients
Qi, Q., & Qi, L. (2012) · Clinical Lipidology · doi:10.2217/clp.12.46 · Cited by 40
Yun, J., Lim, T., Cha, S., Ahn, Y., Song, K., Choi, J. A., Kwon, J. W., Jee, D., Cho, Y. K., Park, Y., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.030 · Cited by 37
Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?
Alfonsi, J., Hegele, R. A., & Gryn, S. E. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0573-6 · Cited by 41
Self-citationKunutsor, S. K., Khan, H. M., Nyyssönen, K., & Laukkanen, J. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.069 · Cited by 36
Gilmore, L. A., Crouse, S. F., Carbuhn, A. F., Klooster, J., Calles, J. A. E., Meade, T. H., & Smith, S. B. (2013) · Nutrition Research · doi:10.1016/j.nutres.2013.09.003 · Cited by 44
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 34
Ferretti, G., Bacchetti, T., Simental‐Mendía, L. E., Reiner, Ž., Banach, M., & Sahebkar, A. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6721-6 · Cited by 35
Dallmeier, D., & Köenig, W. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.01.003 · Cited by 39
Lipoprotein(a) – Link between Atherogenesis and Thrombosis
Labudović, D. D., Kostovska, I., Trajkovska, K. T., Cekovska, S., Kavrakova, J. B., & Topuzovska, S. (2019) · Prague Medical Report · doi:10.14712/23362936.2019.9 · Cited by 30
Koschinsky, M. L., & Boffa, M. B. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.002 · Cited by 33
Self-citationInverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population
Ishikawa, S., Kotani, K., Kario, K., Kayaba, K., Gotoh, T., Nakamura, Y., & Kajii, E. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.11.032 · Cited by 27
Kim, J. J., Chae, S. J., Choi, Y. M., Hwang, K. R., Song, S. H., Yoon, S. H., Kim, S. M., Ku, S., Kim, S. H., Kim, J. G., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det057 · Cited by 28
Lipoprotein (a): Coming of Age at Last
Witztum, J. L., & Ginsberg, H. N. (2016) · Journal of Lipid Research · doi:10.1194/jlr.e066985 · Cited by 28
LPA Gene Polymorphisms and Gene Expression Associated with Coronary Artery Disease
Song, Z., Cao, H., Wu, H., Zhou, L., & Qin, L. (2017) · BioMed Research International · doi:10.1155/2017/4138376 · Cited by 23
Lipoprotein(a) is not associated with venous thromboembolism risk
Kunutsor, S. K., Mäkikallio, T. H., Kauhanen, J., Voutilainen, A., & Laukkanen, J. A. (2019) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2019.1612087 · Cited by 21
High prevalence of cardiovascular disease in South Asians: Central role for brown adipose tissue?
Boon, M. R., Bakker, L. E. H., van der Linden, R. A. D., van Ouwerkerk, A. F., de Goeje, P. L., Counotte, J., Jazet, I. M., & Rensen, P. C. N. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.1003634 · Cited by 23
Кононов, С. И., Маль, Г. С., Azarova, I. E., Klyosova, E. Y., Быканова, М. А., Churnosov, M. I., & Polonikov, A. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0097 · Cited by 20
Genetics of Lipid Traits and Relationship to Coronary Artery Disease
Keenan, T. E., & Rader, D. J. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0396-9 · Cited by 19
Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance
Vassiliou, V. S., Flynn, P. D., Raphael, C. E., Newsome, S., Khan, T. Z., Ali, A., Halliday, B. P., Bruengger, A. A. S., Malley, T. S., Sharma, P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181077 · Cited by 18
Romagnuolo, R., DeMarco, K., Scipione, C. A., Boffa, M. B., & Koschinsky, M. L. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.002 · Cited by 18
Self-citationApolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
Oliveira, C., Fournier, C., Descamps, V., Morel, V., Scipione, C. A., Romagnuolo, R., Koschinsky, M. L., Boullier, A., Marcelo, P., Domon, J.-M., et al. (2017) · Hepatology · doi:10.1002/hep.29096 · Cited by 16
Self-citationDiagnosis and Management of Familial Dyslipoproteinemias
Kwiterovich, P. O. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0371-5 · Cited by 18
Handa, J. T., Tagami, M., Ebrahimi, K. B., Leibundgut, G., Janiak, A., Witztum, J. L., & Tsimikas, S. (2015) · Europe PMC (PubMed Central) · Cited by 21
Bu, S. Y. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.132 · Cited by 16
Cenarro, A., Puzo, J., Ferrando, J., Mateo‐Gállego, R., Bea, A. M., Calmarza, P., Jarauta, E., & Civeira, F. (2013) · Metabolism · doi:10.1016/j.metabol.2013.10.014 · Cited by 16
Boffa, M. B. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0622-1 · Cited by 15
Self-citationMatsushita, K., Hibi, K., Komura, N., Kimura, Y., Matsuzawa, Y., Konishi, M., Maejima, N., Iwahashi, N., Kosuge, M., Ebina, T., et al. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.01.005 · Cited by 14
The efficacy of evolocumab in the management of hyperlipidemia: a systematic review
AlHajri, L., AlHadhrami, A., AlMheiri, S., AlMutawa, Y., & AlHashimi, Z. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717698925 · Cited by 14
Wang, Y., Ma, H., Yang, J., Chen, Q., Lu, L., & Zhang, R. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.59875 · Cited by 13
Živković, M., Stanković, A., Djurić, T., KONCAR, I. B., Kolaković, A., Djurdjević, V., Davidovic, L. B., & Alavantić, D. (2014) · Molecular Biology Reports · doi:10.1007/s11033-013-2962-z · Cited by 13
Zhu, L., Lu, Z., Zhu, L., Ouyang, X., Yang, Y. A. N. G., Feng, Y., Li, P., Ye, W., Zhang, X., ZHANG, X., et al. (2016) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1502-74 · Cited by 12
Sun, L., Zong, M., Chen, C., Xie, L., Wu, F., Yu, M., & Fan, L. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0753-1 · Cited by 11
Kouvari, M., & Panagiotakos, D. B. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000628 · Cited by 11
Síndrome metabólico, lipoproteína(a) y aterosclerosis subclínica en población mexicana
Cardoso-Saldaña, G. C., González-Salazar, M. D. C., Posadas‐Sánchez, R., & Vargas‐Alarcón, G. (2020) · Archivos de cardiología de México · doi:10.24875/acm.20000276 · Cited by 10
Lipoprotein ( a ) and Atherogenic Indices in Sudanese Patients with Type 2 Diabetes
Mohieldein, A., Abdalla, K. E., & Hasan, M. (2014) · International Journal of Health Sciences · doi:10.12816/0023976 · Cited by 11
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients
Peela, J. R., Latiwesh, O. B., Elshaari, F. A., Hussain, A., Tabrez, E. S., Viglianco, E., Edwards, A., Ali, F., & Rawal, A. K. (2018) · Cureus · doi:10.7759/cureus.3030 · Cited by 9
Shalnova, S. A., Владиславович, Е. М., Metelskaya, V. A., Евстифеева, С. Е., Tarasov, V. I., Аркадьевна, М. Г., Balanova, Y. А., Имаева, А. Э., Владимировна, К. А., Shabunova, A. A., et al. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-5-612-621 · Cited by 9
Tüten, A., Gungor, Z., Ekmekçi, H., Ekmekçi, Ö. B., Kücür, M., Yılmaz, N., Donma, O., Sönmez, H. A., Açıkgöz, A. S., & Madazlı, R. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2019.1622667 · Cited by 11
McGowan, M. P., Moriarty, P. M., & Backes, J. M. (2014) · Clinical Lipidology · doi:10.2217/clp.14.43 · Cited by 8
Genetics of Coagulation: What the Cardiologist Needs to Know
Anderson, J. A. M., Lim, W., & Weitz, J. I. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.10.024 · Cited by 8
Abdullah, F. E., & Ahmed, S. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000915 · Cited by 6
de Ávila, B. E., Campuzano, S., Pedrero, M., Salvador, J. ‐., Marco, M. ‐., & Pingarrón, J. M. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-7964-8 · Cited by 5
Modified risk associations of lipoproteins and apolipoproteins by chronic low-grade inflammation
Onat, A., Kaya, A., & Ademoğlu, E. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1417839 · Cited by 5
Dron, J. S., Lazarte, J., & Hegele, R. A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311581 · Cited by 6
Self-citationLi, K., Yang, X., Wang, L., Chen, M., Xu, L., & Yang, X. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.11.023 · Cited by 4
Andriy, L., ́Anna, B. M. M. S., Mykhaylo, V., & Oxana, A. (2012) · InTech eBooks · doi:10.5772/48083 · Cited by 6
Koschinsky, M. L., Boffa, M. B., & Marcovina, S. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00010-4 · Cited by 5
Self-citationLipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk
Phan, B. A. P., & Toth, P. P. (2013) · Clinical Lipidology · doi:10.2217/clp.13.9 · Cited by 3
Depression in Cardiovascular Patients in Middle Eastern Populations: A Literature Review
Donnelly, T. T., Suwaidi, J. M. S. A., Al‐Qahtani, A., Asaad, N., Qader, N. A., Singh, R., Fung, T. S., Mueed, I., Sharara, S., Banna, N. E., et al. (2014) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-014-0052-5 · Cited by 2
What do we know about lipoprotein(a)?
Cybulska, B., & Kłosiewicz−Latoszek, L. (2015) · Kardiologia Polska · doi:10.5603/kp.a2014.0244 · Cited by 2
Estrogen modulates plasminogen promoter activity
Kobelt, L., Klammt, J., Tefs, K., & Schuster, V. H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.035 · Cited by 1
Statin therapy: time for a precision medicine approach?
Mehdar, A., Hegele, R. A., Kim, R. B., & Gryn, S. E. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1356685 · Cited by 1
Self-citationErsonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins
Kachkovsky, M. A., Vvedenskaya, I. P., Vvedensky, V. Y., Supilnikov, A. A., Ponomareva, J. V., & Milyakova, M. N. (2020) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2020.4.11 · Cited by 1
Tchamba, G. (2015) · ScholarWorks - WMU (Western Michigan University)
Dieplinger, B., & Dieplinger, H. (2012) · InTech eBooks · doi:10.5772/51865 · Cited by 2
Metadata
- Authors
- Dubé, J. B., Boffa, M. B., Hegele, R. A., & Koschinsky, M. L.
- Affiliations
- Western University (CA)
- University of Windsor (CA)
- Corresponding author
- Dubé, Joseph B.
- Boffa, Michael B.
- Venue
- Current Opinion in Lipidology
- Published
- 2012-04
- Volume
- 23
- Issue
- 2
- Pages
- 133-140
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2036075350
- Cited by
- 105
- References
- 48
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 11 · 2018: 8 · 2017: 10 · 2016: 20 · 2015: 8 · 2014: 12 · 2013: 15 · 2012: 11
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (79853_1, 79523_1, MOP13430)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), cardiovascular risk, coronary artery disease, inflammation, atherogenesis, thrombosis, antisense oligonucleotides, apolipoprotein(a), pleiotropy, Lp(a) metabolism
- MeSH terms
- Animals, Cardiovascular Diseases, Coronary Disease, Humans, Polymorphism, Genetic, Risk Factors, Lipoprotein(a), Genetic Predisposition to Disease, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.